Long-term results of a Phase Ib trial of Isa-VRd in newly diagnosed transplant-ineligible myeloma

Isatuximab + Len/Dex/Bortezomib vs IsaRd in Newly Diagnosed Transplant Ineligible Multiple MyelomaПодробнее

A trial investigating IberVd in transplant-ineligible newly diagnosed multiple myelomaПодробнее

Overall Survival Results in Transplant-Ineligible Newly Diagnosed MM pts: Phase 3 MAIA StudyПодробнее

Long term follow-up results from the Phase III MAIA trial in myelomaПодробнее

Isa-VRd vs VRd for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (IMROZ)Подробнее

IMROZ: Isa-VRd vs VRd for transplant-ineligible newly diagnosed multiple myelomaПодробнее

Dr Facon on the Implications of Isatuximab Plus VRd in Transplant-Ineligible Newly Diagnosed MyelomaПодробнее

Quadruplets in Newly Diagnosed Transplant-Ineligible MyelomaПодробнее

SKylaRk: Phase II study of Isa-KRD in newly diagnosed, transplant-eligible multiple myelomaПодробнее

Four-year follow-up of GMMG-CONCEPT: efficacy of Isa-KRd in high-risk newly diagnosed myelomaПодробнее

The #ASCO24 Hematology Round UpПодробнее

Data Shows Potential for Change in Standard of Care for Transplant-Ineligible MyelomaПодробнее

The safety and efficacy of Isa-VRd in patients with transplant-ineligible NDMMПодробнее

Isatuximab shows benefit in transplant-ineligible patients with newly diagnosed multiple myelomaПодробнее

A Phase Ib trial of fixed-volume isatuximab infusion in newly-diagnosed multiple myelomaПодробнее

Analyzing isatuximab in quadruplet combinations in transplant-ineligible multiple myelomaПодробнее

Phase III trial of RVd induction with or without isatuximab in newly diagnosed myelomaПодробнее

Isatuximab with VRd in Pts with Newly Diagnosed Multiple Myeloma Non-Eligible for TransplantПодробнее

IMROZ- IsaRVd vs RVd in Newly Diagnosed Transplant Ineligible MM | Thierry Facon, MD | EHA 2024Подробнее